Brief: Bavarian Nordic Keeps Rev Interval, EBITDA Margin Expectations For @025
22/08/2025 06:43
Corrects typo in headline Aug 22 (Reuters) - Bavarian Nordic A/S BAVA.CO: OUTLOOK FY REVENUE DKK 6,000-6,600 MILLION Q2 REVENUE DKK 1,652 MILLION OUR TRAVEL HEALTH BUSINESS CONTINUES TO OUTPERFORM, DELIVERING 24% REVENUE GROWTH YEAR-OVER-YEAR, PRIMARILY DRIVEN BY RABIES AND TBE VACCINES OVERALL, WE REMAIN WITHIN OUR GUIDED REVENUE INTERVAL AND MAINTAIN OUR EXPECTATIONS TO EBITDA MARGIN BEFORE SPECIAL ITEMS OF 26-30% IN 2025 MAJOR HIGHLIGHT FOR PERIOD WAS LAUNCH OF OUR CHIKUNGUNYA VACCINE FOR TRAVELERS, WHICH IS BEING INTRODUCED IN MORE COUNTRIES AS WE CONTINUE TO EXPAND OUR COMMERCIAL FOOTPRINT ACROSS NEW GEOGRAPHIES Source text: ID:nGNE8YNkcW Further company coverage: BAVA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract
Brief: Bavarian Nordic Secures Additional Government Contract For The Supply Of Smallpox/Mpox Vaccine
Brief: Bavarian Nordic Launches Final Tranche Of Buy-Back Program
Bavarian Nordic falls as high costs, lower vaccine sales hit Q1 results
Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline